Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2 Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection.

NCT07641426 is registered in ClinicalTrials.gov with CASI pharmaceuticals, Inc. as lead sponsor.

NCT NCT07641426
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07641426 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2 Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection.
Lead sponsor
CASI pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 9, 2026
Completion date
December 31, 2030
Enrollment
58 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

antibody mediated rejection